you were positive on the stock the whole time you should have been negative, and now you are negative when you should be positive. Maybe someone should be watching over you
Sentiment: Strong Buy
if they get a strong Europe partner this goes to $10 in a flash
hard to believe the stock is trading at cash with 2 very legit phase III chances coming in the next 90 days. if both hit its a 10X easy
stock price makes no sense if one or both of the phase III's are successful. I honestly think the market flushed this stock back in Jan with the rest of the space and it like many other biotechs is sitting near cash valuation. great time to be a speculative investor.
now under construction in IA, IL, and ND. Will be up and running later this year. Will cut deep into CP's gravy train hauling oil from the Bakken. Love it-- couldn't happen to a bigger group of dbags
message was not directed to you. you need to keep working-- the world needs people to screw in bolts. thanks for your service!
the stock market is an incredible place to make money, unlike any other on earth in my opinion. you just have to know what you are doing. this is the time to buy AEZS, sell in late Q3 for a 100% gain. find one or two opportunities like that per year and you wont have to work anymore. never hold through phase III results or pdufa dates-- stupid and not necessary to get rich (maybe let 20% ride if you are a gambler). most biotechs stumble through the process and screw it up at least once-- the former failures with 130 are ancient history. the market looks forward even if you personally are looking back --
Sentiment: Strong Buy
yo bro, you are obviously quite bitter about your losses here- not surprised given the history. AEZS is burning about $10M per quarter, but only about $1.5M of that is due to the sales force. I don't quite get the need to establish a commercial presence either, but the fact is that it wouldn't be that hard to achieve break even with just a modest ramp in sales of one of the products. Overall, this is not a pump and dump. Their 2 phase III's have a legit shot, and its not like the stock is all pumped up in advance-- its trading at cash. Zoptrex as a LHRH agonist has precedent with Cetrorlix and if it works this is a $40 stock. Decent gamble here and expect a good ramp in price leading up to Q4
they must think people are idiots. oh yeah, they are right